<DOC>
	<DOCNO>NCT01254045</DOCNO>
	<brief_summary>The purpose study determine whether medication oxytocin effective tolerable treatment adolescent male fragile X syndrome ( FraX ) improve socially appropriate behavior reduce social anxiety .</brief_summary>
	<brief_title>Double-blind Placebo Controlled Study Oxytocin Fragile X Syndrome</brief_title>
	<detailed_description>Twelve male adolescent ( 13-24 year ) subject confirm genetic diagnosis FraX ( full mutation ) participate randomize double-blind placebo-controlled study . They receive dose either 24 IU oxytocin , 48 IU oxytocin placebo three visit lab , visit space one week apart . The efficacy dose evaluate use behavioral , cognitive physiological metric . If individual subject result suggest either oxytocin dosage level ( 24 IU 48 IU ) superior placebo double-blind phase , single-blind trial use optimal dosage oxytocin administer daily 14 day parent home . Subjects come lab final assessment Day 30 . Determination beneficial response oxytocin base 20 % change ( improvement ) behavior test performance ( see ) . If oxytocin dosage level provide similar benefit compare placebo , low dose chosen 14 day single-blind trial .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Confirmed genetic diagnosis Fragile X ( FraX ) ( full mutation ) . 2 . Male ( serious effect due X chromosome nature disorder ) 3 . Age 1329 year . 4 . Parent adolescent must willing sign inform consent . 5 . Intelligence Quotient ( IQ ) &gt; 42 . 1 . Cardiac risk factor . 2 . Medication exclusion : opiate opiate antagonist , corticosteroid , typical atypical antipsychotic .</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>